Ted Omachi is a Medical Director in the Product Development Immunology group at Genentech, focusing on late-stage development in respiratory and allergic diseases. He joined Genentech in 2013, starting in the Medical Affairs group before transitioning to Product Development in 2015. At Genentech, he has served as Clinical Science Team Leader, Medical Monitor and Medical Team Leader for Phase 2, Phase 3 and Phase 4 programs in atopic dermatitis, nasal polyposis, chronic urticaria and asthma. This work has involved overall clinical development planning, obtaining written and in-person regulatory feedback, study protocol writing, study execution, statistical analysis plan development, Key Opinion Leader interaction, interpretation of trial results, aligning with business partners, post-hoc analyses, publication and regulatory submissions.
Prior to joining the industry, Ted was an Assistant Professor in pulmonary division at the University of California San Francisco, where he conducted clinical research in obstructive lung diseases and sleep disorders. He was in the midst of a K-23 award from NIH-NHLBI at the time that he left his full-time position at UCSF; he continues to volunteer in the clinic there. Ted is board-certified in pulmonary, critical care, and sleep medicine, having completed his residency and fellowships at UCSF, medical school at UC San Diego, obtained his MBA from UC Berkeley, and his undergraduate degree at Harvard University. He is a native of San Francisco.
